Stephens upgraded Evolent Health (EVH) to Overweight from Equal Weight with an unchanged price target of $7.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- BMO Capital’s Optimistic Buy Rating for Evolent Health Driven by Strategic Stabilization and Growth Initiatives
- Evolent Health initiated with an Outperform at BMO Capital
- Evolent Health price target lowered to $12 from $18 at Oppenheimer
- Evolent Health price target lowered to $11 from $13 at Citizens JMP
- Evolent Health Inc. Reports Strong Q3 Earnings and Strategic Growth